2017 The Oncolytic Virus Landscape Industry Trends & Opportunities Market Research Hub has recently announced the addition of a new report to it broad database titled as“ The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities”. The field of oncolytic viruses was quite dormant in the first decade of the 2000s, characterized by slow clinical progress due to hypercautiousness and low, albeit steady, investments.
Request for Sample Report: http:// www. marketresearchhub. com / enquiry. php? type = S & repid = 94 3738
The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities
The takeover of BioVex by Amgen in late 2011, worth up to US $ 1 bln, has woken up the field and became a game changer together with the 2015 approval of the first oncolytic virus Imlygic developed by BioVex in regulated markets. In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also „ freed“ tumor specific neoantigens, indirectly acting as a cancer vaccine.
However, the efficacy of oncolytic viruses still was modest, but can be improved when combined with immune checkpoint inhibitors. This lead to an increased partnering interest of the major immuno-oncology( I-O) players, but also of investors who view oncolytic viruses as a must be for I-O combination regimens. As a consequence, total venture equity and